News

PAH specialists discuss upfront combination therapy and the disconnect between guidelines and community practice.

Genetic variants tied to CAR T toxicity and expansion could guide how researchers screen healthy donors for allogeneic CAR T products.

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

Lp(a) is one of the biggest contributors to cardiovascular disease, but recent studies have shown that awareness of and testing for the condition is subpar nationwide.

Deupirfenidone 825 mg reduced 26-week FVC decline by 91.0 mL versus placebo in the phase 2b ELEVATE-IPF trial in idiopathic pulmonary fibrosis.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.

A randomized TMS trial found lower DLPFC electric-field strength, not higher intensity, correlated with greater depression improvement.

The Fast Track designation adds to LTI-03's prior Orphan Drug status as Rein Therapeutics advances the Phase 2 RENEW trial in IPF.

The FDA granted accelerated approval to the first gene therapy for GSD1a, based on a 31% reduction in daily cornstarch intake versus placebo.

Academic pulmonologists from Mass General, Duke, and Cleveland Clinic discuss biologic selection, mucus plugging, and more.

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

Melinda Gooderham, MD, MSc, discusses new JAMA data on upadacitinib's efficacy for severe alopecia areata in adults and adolescents.

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

Remick discusses multidisciplinary teams, adherence issues, and the path forward for heart failure care in this post-forum interview.

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

Brian Vickery, MD, discusses the mechanism, dose-escalation design, and outlook for a first-in-human microneedle immunotherapy trial for peanut allergy.

Robert Sarkany, MD, FRCP, discusses PORT-77's phase 2a safety profile in EPP and the endpoints to watch as the drug advances to phase 2b/3.

The first-in-class D1 receptor antagonist earns Priority Review and Orphan Drug designation, with an FDA action date late in Q1 2027.

Investigators outline how phase 1 safety data could inform a phase 2 efficacy study and eventual pediatric enrollment down to age 4 years.

In this interview, Robert Sarkany, MD, FRCP, explains the biology behind erythropoietic protoporphyria and how PORT-77 targets its underlying cause.

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

The first-in-human study is testing an ascending-dose microneedle device designed to deliver peanut protein through the skin in just 3 minutes.

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

Philippe Généreux, MD, discusses a secondary analysis of EARLY TAVR examining patients excluded from the trial for positive treadmill stress tests.

A biomarker study links immune signaling (IL-7/IL-15) and brain gamma-wave activity to ketamine response in TRD.

Tiffany Mayo, MD, reflects on the pressure of visibility in medical leadership and why boundary-setting becomes essential.

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents